Ambitious study will profile thousands of tumor samples to uncover novel biomarkers and therapeutic targets for cancer and inflammatory diseases 10x Gen...
Addgene, a purpose-driven organization helping scientists conduct experiments with greater ease, speed, and reproducibility, announced a strategic ...
Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd. announced that the U.S. Food and Drug Administrat...
The partnership combines Secarna’s OligoCreator® technology with Vect-Horus’ VECTrans® platform to enable system...
Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers, announced that it...
Hongene Biotech Corporation, a contract development and manufacturing organization (CDMO) specializing in nucleic acid therapeutics, announced its ...
Shanghai Zhimeng Biopharma, Inc. ("Zhimeng Biopharma"), a clinical-stage biopharmaceutical company dedicated to innovative drug development for liver and...
Purespring Therapeutics, a precision nephrology company focused on transforming the treatment of kidney diseases, announces that the U.S. Food and Drug A...
Amarna Therapeutics, (“Amarna” or “the Company”), a privately held biotechnology company pioneering transformative gene therapies...
Abinopharm, Inc., an innovative nutritional and biopharmaceutical company based in Shelton, Connecticut, USA, is pleased to announce that its partner, EG...
MaaT Pharma and Clinigen signed exclusive long-term licensing and distribution agreement and commercial supply agreement for Xervyteg® (MaaT013),...
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Adva...
HUTCHMED (China) Limited announces that the New Drug Application (“NDA”) for the combination of ORPATHYS® (savolitinib) and TAGRISS...
In a significant move to accelerate the global fight against blood cancers and hard-totreat solid tumours, renowned end- to-end biologics CDMO Mabion hav...
© 2025 Biopharma Boardroom. All Rights Reserved.
